Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA

• Carolina Ruiz B ^[1] ; Mario Delgado D ^[2] ; Carolina Martinez C ^[1] ; Alicia Valdivieso V ^[1] ; Carmen Gloria Aylwin H ^[1] ; Carlos Deck R ^[1] ; Milton Alcaino I ^[1]
  1. [1] Hospital Dipreca

     Hospital Dipreca

     Santiago, Chile

     
  2. [2] Universidad de Chile

     Universidad de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 135, Nº. 5, 2007, págs. 573-579
• Idioma: español
• Títulos paralelos:
  • Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients
• Enlaces
  • Texto completo
• Resumen

  • Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report the experience in our Health Centre with rapamycin-eluting stents. Patients and methods: Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed. Results: Twenty-nine subjects (90.6%) remained asymptomatic, two subjects (6.3%) developed angina pectoris but restenosis was ruled out, and one subject (3.1%) died. Conclusions: The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Study